Chimeric Antigen Receptor T Cell Preparation Targeting Claudin18.2
Gastric Cancer
Explore 281 assets in Gastric Cancer →Floatz Rating
D28/100
Confidence
Indicative
Sponsor
The Affiliated Hospital of Qingdao University
Modality
Cell therapy
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05952375CT.gov Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chimeric Antigen Receptor T Cell Preparation Targeting Claudin18.2 (this asset) | The Affiliated Hospital of Qingdao University | N/A | D · 28 |
| Fluorouracilum | I-Mab Biopharma US Limited | P4 | BB |
| Rivoceranib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P4 | BB |
| Oxaliplatin | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Irinotecan | Shenzhen Xinhe Biomedical | P4 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Epirubicin | Rondo Therapeutics | P3 | B |
| Cyclophosphamide | Vall d'Hebron Institute of Oncology | P3 | B |
+42 more in the Gastric Cancer cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chimeric Antigen Receptor T Cell Preparation Targeting Claudin18.2 in Gastric Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chimeric-antigen-receptor-t-cell-preparation-targeting-claudin182-gastric-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →